References
- Bai S, Thomas C, Rawat A, Ahsan F. (2006). Recent progress in dendrimer-based nanocarriers. Crit Rev Ther Drug Carrier Syst, 23, 437–495.
- Bavdek A, Gekara NO, Priselac D, et al. (2007). Sterol and pH interdependence in the binding, oligomerization, and pore formation of Listeriolysin O. Biochemistry, 46, 4425–4437.
- Belting M, Sandgren S, Wittrup A. (2005). Nuclear delivery of macromolecules: barriers and carriers. Adv Drug Deliv Rev, 57, 505–527.
- Douziech-Eyrolles L, Marchais H, Hervé K, et al. (2007). Nanovectors for anticancer agents based on superparamagnetic iron oxide nanoparticles. Int J Nanomed, 2, 541–550.
- D’Souza B, Berdichevsky F, Kyprianou N, Taylor-Papadimitriou J. (1993). Collagen-induced morphogenesis and expression of the alpha 2-integrin subunit is inhibited in c-erbB2-transfected human mammary epithelial cells. Oncogene, 8, 1797–1806.
- El-Sayed A, Futaki S, Harashima H. (2009). Delivery of macromolecules using arginine-rich cell-penetrating peptides: ways to overcome endosomal entrapment. AAPS J, 11, 13–22.
- Fretz MM, Høgset A, Koning GA, Jiskoot W, Storm G. (2007). Cytosolic delivery of liposomally targeted proteins induced by photochemical internalization. Pharm Res, 24, 2040–2047.
- Gekara NO, Jacobs T, Chakraborty T, Weiss S. (2005). The cholesterol-dependent cytolysin listeriolysin O aggregates rafts via oligomerization. Cell Microbiol, 7, 1345–1356.
- Glickson JD, Lund-Katz S, Zhou R, et al. (2009). Lipoprotein nanoplatform for targeted delivery of diagnostic and therapeutic agents. Adv Exp Med Biol, 645, 227–239.
- Glomski IJ, Gedde MM, Tsang AW, Swanson JA, Portnoy DA. (2002). The Listeria monocytogenes hemolysin has an acidic pH optimum to compartmentalize activity and prevent damage to infected host cells. J Cell Biol, 156, 1029–1038.
- Jacobs T, Darji A, Frahm N, et al. (1998). Listeriolysin O: cholesterol inhibits cytolysis but not binding to cellular membranes. Mol Microbiol, 28, 1081–1089.
- Karanth H, Murthy RS. (2007). pH-sensitive liposomes—principle and application in cancer therapy. J Pharm Pharmacol, 59, 469–483.
- Kommareddy S, Tiwari SB, Amiji MM. (2005). Long-circulating polymeric nanovectors for tumor-selective gene delivery. Technol Cancer Res Treat, 4, 615–625.
- Kong G, Braun RD, Dewhirst MW. (2001). Characterization of the effect of hyperthermia on nanoparticle extravasation from tumor vasculature. Cancer Res, 61, 3027–3032.
- Kullberg M, Mann K, Owens JL. (2009). A two-component drug delivery system using Her-2-targeting thermosensitive liposomes. J Drug Target, 17, 98–107.
- Lee KD, Oh YK, Portnoy DA, Swanson JA. (1996). Delivery of macromolecules into cytosol using liposomes containing hemolysin from Listeria monocytogenes. J Biol Chem, 271, 7249–7252.
- Mandal M, Kawamura KS, Wherry EJ, Ahmed R, Lee KD. (2004). Cytosolic delivery of viral nucleoprotein by listeriolysin O-liposome induces enhanced specific cytotoxic T lymphocyte response and protective immunity. Mol Pharm, 1, 2–8.
- Needham D, Anyarambhatla G, Kong G, Dewhirst MW. (2000). A new temperature-sensitive liposome for use with mild hyperthermia: characterization and testing in a human tumor xenograft model. Cancer Res, 60, 1197–1201.
- Sasaki K, Kogure K, Chaki S, Nakamura Y, Moriguchi R, Hamada H, Danev R, Nagayama K, Futaki S, Harashima H. (2008). An artificial virus-like nano carrier system: enhanced endosomal escape of nanoparticles via synergistic action of pH-sensitive fusogenic peptide derivatives. Anal. Bioanal. Chem, 391, 2717–27.
- Schnupf P, Portnoy DA. (2007). Listeriolysin O: a phagosome-specific lysin. Microbes Infect, 9, 1176–1187.
- Stahl R, Wang T, Lindner LH, et al. (2009). Comparison of radiological and pathohistological response to neoadjuvant chemotherapy combined with regional hyperthermia (RHT) and study of response dependence on the applied thermal parameters in patients with soft tissue sarcomas (STS). Int J Hyperthermia, 25, 289–298.
- Torchilin VP, Weissig V. (2003). Liposomes (pp. 34–35 ). Oxford: Oxford University Press.
- Worthylake R, Opresko LK, Wiley HS. (1999). ErbB-2 amplification inhibits down-regulation and induces constitutive activation of both ErbB-2 and epidermal growth factor receptors. J Biol Chem, 274, 8865–8874.
- Xu S, Luo Y, Graeser R, et al. (2009). Development of pH-responsive core-shell nanocarriers for delivery of therapeutic and diagnostic agents. Bioorg Med Chem Lett, 19, 1030–1034.